No comments yet. Be the first to say something!
📚 Part of the TILA-278 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. Module 2.1 — CTD Table of Contents (TILA-278)
Why it exists. A high-level CTD summary a reviewer reads first; it distils the underlying reports.
How it is produced here. It contains no new data. It is a distillation — it gathers, summarizes, and cross-references the underlying study reports and datasets into the shorter form a regulator reads first.
Format & governing standard. —
Document ID: M21
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): ICH M4
This application comprises the Module 2–5 documents listed below. Module 1 regional administrative content is indexed in the regional Module 1 submission; the Trial Master File, program-management, and quality-system records are maintained outside the eCTD.